


Aspira Women's Health Email Formats
Biotechnology Research • Trumbull, Connecticut, United States • 51-100 Employees
Aspira Women's Health Email Formats
Aspira Women's Health uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@aspirawh.com), used 56.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@aspirawh.com | 65.6% |
{first name}{last name} | johndoe@aspirawh.com | 31.3% |
{last name}{last name} | doedoe@aspirawh.com | 3.1% |
Key Contacts at Aspira Women's Health
Cynthia Hundorfean
Member, Board Of Directors
Jamie Sullivan
Senior Director Of Corporate Functions, Arpa-H Program Director, & Chief Of Staff
Kristi Mccaughan
Senior Regional Account Director, Field Sales Trainer
John Leavitt
Director Of Laboratory Operations
Jack Fraser
Member Board Of Directors
Mauricio Chaimowicz
Regional Account Director
Leo B Twiggs
Director Of Medical Affairs
Christina Sanderson
Regional Account Director
Winfred Parnell
Board Director | Member, Nominations & Governance Committee | Member, Compensation Committee
Company overview
| Headquarters | 35 Nutmeg Drive, Suite 260, Trumbull, Connecticut 06611, US |
| Phone number | +18442774721 |
| Website | |
| NAICS | 541714 |
| SIC | 382 |
| Founded | 1993 |
| Employees | 51-100 |
| Socials |
About Aspira Women's Health
Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer. Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite℠, which includes OvaWatch℠, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus® combines our FDA-cleared products, Ova1® and Overa®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery. EndoCheck℠, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Aspira Women's Health has 37 employees across 13 departments.
Departments
Number of employees
Funding Data
Explore Aspira Women's Health's funding history, including investment rounds, total capital raised, and key backers.
Aspira Women's Health Tech Stack
Discover the technologies and tools that power Aspira Women's Health's digital infrastructure, from frameworks to analytics platforms.
Miscellaneous
Form builders
Form builders
JavaScript frameworks
JavaScript libraries
WordPress plugins
JavaScript libraries
Miscellaneous
WordPress plugins
JavaScript libraries
JavaScript graphics
CDN
Frequently asked questions
4.8
40,000 users



